Tamo 20 tablets

Safety advisory

1 November 2017

Tamo 20 tablets may pose a serious risk to your health and should not be taken.

Tamo 20 tablets are not related to the approved medicine Tamoxifen Citrate.

Tamo 20 tablets and packaging.

    The Therapeutic Goods Administration (TGA) has tested a product labelled Tamo 20 tablets and found that:
  • The tablets contain the substance tamoxifen at a strength lower than that described on the bottle.

The supply of Tamo 20 tablets is illegal as they are considered to be counterfeit.

Tamo 20 tablets have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA..

TGA investigations have shown that a number of people in Australia may have bought the product online.

Information for consumers

  • Stop taking Tamo 20 tablets and take any remaining tablets to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with the Australian Border Force (ABF) to help stop future shipments of Tamo 20 tablets from entering Australia.

If these tablets are found at the border by the ABF they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites and has produced a short video on the risks associated with buying medicines and medical devices online. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653

Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products

Email: